MDXG (MiMedx Group) Insider Ownership: 14.15 % (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXG MiMedx Group Inc MDXG
57 GF Score
Price $4.35
GF Value $6.52
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is MiMedx Group Insider Ownership?

MiMedx Group MDXG +3.21% 57 Insider Ownership is 14.15 % as of Aug. 19, 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.52 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MiMedx Group's insider ownership is 14.15%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MiMedx Group's Institutional Ownership is 75.94%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MiMedx Group's Float Percentage Of Total Shares Outstanding is 79.02%.

MiMedx Group Insider Ownership Historical Data

* Premium members only.

The historical data trend for MiMedx Group's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiMedx Group Insider Ownership Chart

MiMedx Group Historical Data

The historical data trend for MiMedx Group can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 13.29 13.29 13.29 13.29 13.22 13.22 13.13 13.70 13.86 14.15
MDXG
57GF Score
MiMedx Group Inc MDXG
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiMedx Group Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 14.15 % mean?
MiMedx Group (MDXG) has a Insider Ownership of 14.15 % as of Aug. 19, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on MiMedx Group and its competitors.
Is MiMedx Group's Insider Ownership too high?
MiMedx Group's current Insider Ownership is 14.15 %. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Insider Ownership compare to RGNX and ACHV?
MiMedx Group's Insider Ownership of 14.15 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on MiMedx Group and its competitors. MiMedx Group's current Insider Ownership is 14.15 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.35 — trading 33.3% below its estimated fair value. The current Insider Ownership is 14.15 %. MiMedx Group's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Insider Ownership is 14.15 % as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $4.35 is trading 33.3% below its estimated GF Value™ of $6.52. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Insider Ownership: 14.15 %
  • GF Value™: $6.52 vs. price of $4.35 (33.3% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score

Get the complete analysis for MDXG

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.35
Price
$6.52
GF Value